7 results about "CYP1B1" patented technology

The present invention provides a near-infrared fluorescent probe targeting CYP1B1 enzyme and its preparation and use. The near-infrared fluorescent probe has a structural formula as shown in formula (I): wherein X=O or X=NH, located at the 4' position or the 5' position; Y is a connecting chain, comprising multiple ethylene glycol fragments or multiple alkyl groups. The present invention also relates to the use of the aforementioned probe, wherein the probe targets the specifically expressed tumor marker CYP1B1 enzyme and images the tumor site by specifically binding to the CYP1B1 enzyme. The probe will promote the application of molecular imaging probes in tumor imaging and has good application prospects and clinical transformation value in early diagnosis of tumors.

The invention discloses application of CYP1B1 and AKR1C3 as drug targets for detecting or treating cystitis. The application is specifically as follows: 1) application of CYP1B1 and AKR1C3 as treatment targets in treatment of cystitis; and 2) application as a drug target in detection of cystitis. CYP1B1 and AKR1C3 which are found for the first time and are derived from human can be used as new molecular drug targets for detecting or treating the cystitis, and the drug targets are utilized to realize the purpose of detecting or treating the cystitis, so that a new thought and a gene resource are provided for preventing and treating the cystitis.

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.

To provide novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions.SOLUTION: The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment or prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described in the invention in treating cancer.SELECTED DRAWING: Figure 1

The present invention provides the use of an siRNA and paclitaxel composition in the preparation of a drug for treating hepatocellular carcinoma, wherein the composition is composed of siCYP1B1, siP-gp and paclitaxel in a ratio of 1:1:1. Based on research on increased expression of CYP1B1 and P-gp proteins in hepatocellular carcinoma under hypoxia and reduced drug sensitivity of hepatocellular carcinoma to paclitaxel under hypoxia, the present invention seeks siRNA that can target and knock down CYP1B1 and P-gp. The present invention uses siRNA to target and knock down CYP1B1 and P-gp, thereby reducing the expression of CYP1B1 and P-gp, reversing the drug resistance of hepatocellular carcinoma to paclitaxel, and enhancing the cell cycle arrest mediated by paclitaxel.

To provide novel compounds for use in the treatment or prevention of cancer and other proliferative conditions. [Solution] The present invention relates to novel compounds for use in the treatment or prevention of cancer and other proliferative conditions, characterized, for example, by cells expressing cytochrome P450 1B1 (CYP1B1) and its allele variants. The present invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapies, for example, in the treatment or prevention of cancer or other proliferative conditions, as well as methods for treating cancer or other conditions in human or non-human animal patients. The present invention also provides methods for identifying novel compounds for use in the treatment or prevention of cancer and other proliferative conditions, characterized, for example, by cells expressing CYP1B1 and its allele variants. The present invention also provides methods for determining the efficacy of the compounds of the present invention in cancer treatment.

The invention discloses a novel CYP1B1 enzyme degradation agent as well as a preparation method and application thereof, and particularly discloses a CYP1B1 enzyme targeted hydrophobic tag HyT degradation agent which comprises an affinity ligand, a hydrophobic tag and a connecting chain for connecting the affinity ligand and the hydrophobic tag, each of the affinity ligand and the hydrophobic tag comprises an alpha-naphthylflavone derivative; the connecting chain comprises a plurality of repetitive units, and the repetitive units are composed of ethylene glycol fragments or alkyl groups. The invention also discloses a preparation method of the hydrophobic tag HyT degradation agent and application of the hydrophobic tag HyT degradation agent or a pharmaceutical composition thereof. The novel CYP1B1 enzyme degradation agent provided by the invention has stronger CYP1B1 enzyme targeting capability, and can specifically target tumors, realize sensitization anti-PD-L1 monoclonal antibody immunotherapy and enhance the tumor immunotherapy effect.